

## DAFTAR PUSTAKA

1. Pereira AA, de Oliveira Andrade A, de Andrade Palis A, Cabral AM, Barreto CGL, de Souza DB, et al. Non-pharmacological treatments for COVID-19: current status and consensus. *Research on Biomedical Engineering* 2021;19.
2. World Health Organization. Coronavirus disease (COVID-19). 2021;
3. Kementerian Kesehatan RI. Pedoman Pengendalian dan Pencegahan Coronavirus Disese (COVID-19). Jakarta: Kementrian Kesehatan Republik Indonesia; 2020.
4. Ye ZW, Yuan S, Yuen KS, Fung SY, Chan CP, Jin DY. Zoonotic Origins of Human Coronaviruses. *International Journal of Biological Sciences* 2020;
5. Kementerian Kesehatan RI. Situasi Terkini Perkembangan Coronavirus Disease (COVID-19) 2 Maret 2020 [Internet]. *Infeksi Emerging* 2020 [cited 2024 Mar 18]; Available from: <https://infeksiemerging.kemkes.go.id/situasi-infeksi-emerging/situasi-terkini-perkembangan-coronavirus-disease-covid-19-2-maret-2020>
6. World Health Organization. Coronavirus. 2020;
7. Kementerian Kesehatan RI. Middle East Respiratory Syndrome (MERS) [Internet]. *Infeksi Emerging* 2020 [cited 2024 Mar 18]; Available from: <https://infeksiemerging.kemkes.go.id/penyakit-virus/middle-east-respiratory-syndrome-mers>
8. Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *The Lancet* 2020;395(10242):1973–87.
9. Ferguson NM, Laydon D, Nedjati-Gilani G, Imai N, Ainslie K, Baguelin M, et al. Report 13: Estimating the number of infections and the impact of non-pharmaceutical interventions on COVID-19 in 11 European countries. Imperial College COVID-19 Response Team [Internet] 2020;(March). Available from: <https://doi.org/10.25561/77482>.
10. World Health Organization. Non-pharmaceutical public health measures for mitigating the risk and impact of epidemic and pandemic influenza. WHO; 2019.
11. Odusanya OO, Odugbemi BA, Odugbemi TO, Ajisegiri WS. COVID-19: A review of the effectiveness of non-pharmacological interventions. *Nigerian Postgraduate Medical Journal* 2020;27(4):261–7.
12. World Health Organization. WHO Coronavirus (COVID-19) Dashboard [Internet]. WHO2023 [cited 2023 Nov 9]; Available from: <https://covid19.who.int/>
13. Gasperek M, Racko M, Dubovsky M. A stochastic, individual-based model for the evaluation of the impact of non-pharmacological interventions on COVID-19 transmission in Slovakia. *medRxiv* 2020;2020.05.11.20096362.
14. Aljohani NI, Mutai K. Effect of non-pharmacological interventions on the COVID-19 epidemic in Saudi Arabia. *Epidemiology and Infection* 2021;149:1–10.
15. Patel P, Athotra A, Vaisakh TP, Dikid T, Jain SK. Impact of nonpharmacological interventions on COVID-19 transmission dynamics in India. *Indian journal of public health* 2020;64:S142–6.
16. Mendez-Brito A, El Bcheraoui C, Pozo-Martin F. Systematic review of empirical studies comparing the effectiveness of non-pharmaceutical interventions against COVID-19. *Journal of Infection* [Internet] 2021;83(3):281–93. Available from:

- <https://doi.org/10.1016/j.jinf.2021.06.018>
17. Ahmad Z. *Praktis Covid-19*. Palembang: FK UNSRI; 2020.
  18. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19. 2020;
  19. World Health Organization. WHO COVID-19 dashboard [Internet]. WHO2024 [cited 2024 Mar 13]; Available from: <https://data.who.int/dashboards/covid19/deaths?n=c>
  20. Kementerian Kesehatan RI. DASHBOARD COVID-19 [Internet]. Kementerian Kesehatan RI2024 [cited 2024 Mar 30]; Available from: <https://dashboardcovid19.kemkes.go.id/%0D>
  21. Kementerian Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/413/2020 Tentang Pedoman Pencegahan dan Pengendalian Coronavirus Disease 2019 (COVID-19). Jakarta: Kementerian Kesehatan Republik Indonesia; 2020.
  22. Susilo A, Rumende CM, Pitoyo CW, Santoso WD, Yulianti M, Herikurniawan, et al. Coronavirus Disease 2019: Tinjauan Literatur Terkini. *Jurnal Penyakit Dalam Indonesia* 2020;7(1).
  23. Hayya AW. Penggunaan Klorokuin pada Infeksi Virus COVID-19. *Jurnal Inovasi Penelitian* 2021;18.
  24. Mivtahurrahimah. *Penilaian Perubahan Perilaku Adaptasi Kebiasaan Baru Menghadapi Pandemi COVID-19 di Sumatera Barat*. 2021;
  25. World Health Organization. Transmisi SARS-CoV-2 implikasi terhadap kewaspadaan pencegahan infeksi : Pernyataan keilmuan. 2020.
  26. Hidayani WR. Faktor Faktor Risiko Yang Berhubungan Dengan COVID 19 : Literature Review. *Jurnal Untuk Masyarakat Sehat (JUKMAS)* 2020;4(2).
  27. Escalera-Antezana JP, Lizon-Ferrufino NF, Maldonado-Alanoca A, Alarcón-De-la-Vega G, Alvarado-Arnez LE, Balderrama-Saavedra MA, et al. Risk factors for mortality in patients with Coronavirus Disease 2019 (COVID-19) in Bolivia: An analysis of the first 107 confirmed cases. *Le Infezioni in Medicina* 2020;28(2).
  28. Cen Y, Chen X, Shen Y, Zhang XH, Lei Y, Xu C, et al. Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019da multi-centre observational study. *Clinical Microbiology and Infection* 2020;26:1242–7.
  29. Liu W, Tao ZW, Wang L, Yuan ML, Liu K, Zhou L, et al. Analysis of Factors associated with disease outcomes in hospitalized patient with 2019 novel coronavirus disease. *Chinese Medical Journal* 2020;133(9):1033–8.
  30. Ferdinand K, Batieste T, Fleurestil M. Contemporary and Future Concepts on Hypertension in African Americans: COVID-19 and Beyond. *Journal of The National Medical Association* 2020;112(3):315–23.
  31. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA* 2020;323(11):1061–9.
  32. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. *Clinical Research in Cardiology* 2020;109(5):531–8.
  33. Yunus NR, Rezki A. Kebijakan Pemberlakuan Lockdown Sebagai Antisipasi Penyebaran Corona Virus Covid-19. *Jurnal Sosial & Budaya Syar-i FSH UIN Syarif Hidayatullah Jakarta* 2020;7(3):227–38.
  34. Balkhi F, Nasir A, Zehra A, Riaz R. Psychological and Behavioral Response to the Coronavirus (COVID-19) Pandemic. *Cureus* 2020;12(5).
  35. Abdullah I. COVID-19: Threat and Fear in Indonesia. *American Psychological Association* 2020;12(5):488–490.

36. Muto K, Yamamoto I, Nagasu M, Tanaka M, Wada K. Japanese citizens' behavioral changes and preparedness against COVID-19. *PLOS ONE* 2020;
37. Polack F, Thomas S, Kitchin N et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 2020;383(27):2603–15.
38. Wang Y, Zhang D, Du G et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *The Lancet* 2020;395(10236):1569–78.
39. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *New England Journal of Medicine* 2021;384(5):403–16.
40. Fajri I, Nurhamsyah D, Aisyah S, Mudrikah KA, Azjurnia AR. Terapi Non-Farmakologi dalam Mengurangi Tingkat Nyeri pada Pasien Kanker Payudara Stadium 2-4: Literature Review. *Jurnal Ilmiah Keperawatan Indonesia (JIKI)* 2022;5(2):106.
41. World Health Organization. Advice on use of Masks in the Context of COVID-19. Interim Guidance 2020;
42. Majid J. Perlakuan Social Distancing: Upaya Masyarakat dan Tenaga Medis Dalam Mengurangi Penyebaran Virus Corona COVID-19. *Jurnal Multidisiplin Dehasen (MUDE)* 2022;1(2):61–8.
43. Nursalam, Kusnanto, Mishbahatul E, Yusuf A, Kurniawati ND, Sukartini T, et al. Pedoman Penyusunan Literature dan Systematic Review. Fakultas Keperawatan Universitas Airlangga; 2020.
44. Kitchenham B. Procedures for Performing Systematic Reviews. Garden Street, Eversleigh: Keele University; 2004.
45. Siswanto. Systematic Review sebagai Metode Penelitian untuk Mensintesis Hasil-Hasil Penelitian (Sebuah Pengantar). *Buletin Penelitian Sistem Kesehatan* 2010;13(4):326–333.
46. Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ Global Health* 2021;372(71).
47. IDEAS. Intervensi Non Farmasi untuk Pandemi. [www.ideas.or.id](http://www.ideas.or.id) 2020;
48. Vynnycky E, Whithe R. Infectious Disease Modeling. New York, United State: Oxford University Press; 2010.
49. Jayaweera M, Dannangoda C, Dilshan D, Dissanayake J, Perera H, Manatunge J, et al. Grappling with COVID-19 by imposing and lifting non-pharmaceutical interventions in Sri Lanka: A modeling perspective. *Infectious Disease Modelling* 2021;6:820–31.
50. Yang B, Huang AT, Garcia-Carreras B, Hart WE, Staid A, Hitchings MDT, et al. Effect of specific non-pharmaceutical intervention policies on SARS-CoV-2 transmission in the counties of the United States. *Nature Communications* 2021;12(1):4–13.
51. Klausner Z, Fattal E, Hirsch E, Shapira SC. A single holiday was the turning point of the COVID-19 policy of Israel. *International Journal of Infectious Diseases* 2020;101:368–73.
52. Jorge DCP, Rodrigues MS, Silva MS, Cardim LL, da Silva NB, Silveira IH, et al. Assessing the nationwide impact of COVID-19 mitigation policies on the transmission rate of SARS-CoV-2 in Brazil. *Epidemics* 2021;35(March).
53. Lei H, Wu X, Wang X, Xu M, Xie Y, Du X, et al. Different Transmission Dynamics of Coronavirus Disease 2019 (COVID-19) and Influenza Suggest the Relative Efficiency of Isolation/Quarantine and Social Distancing Against COVID-19 in China. *Clinical Infectious Diseases* 2021;73(11):E4305–11.